TLR3 and neoplasm: Systemic administration of Flt3L, followed by a TLR3 agonist poly(I:C) or CD40 agonist, has been reported to induce the expansion and activation of tumor-residing cDC1s and enhances tumor responses to anti-PD-L1 therapy [15, 35].